Economic Research: U.S. Weekly Financial Notes: I'll See Your Law And Raise You A Bill Jan 13

  • ID: 2386414
  • January 2013
  • Region: United States
  • Standard & Poors
1 of 2

Not to be outdone by the Senate's move to push through legislation before the Jan. 1 sequester, the House of Representatives voted to suspend the nation's statutory borrowing limit until May 18. Aptly called the "No Budget, No Pay Act," it included a provision that docks the pay of lawmakers if one of the chambers of Congress fails to pass a budget blueprint by April 15. Economic releases this week include: Existing home sales in the U.S. fell 1% to an annual rate of 4.94 million units in December from a downwardly revised 4.99 million (previously 5.04 million) in November. New home sales in the U.S. fell an even larger 7.3% in December, to an annual rate of 369,000 units,...

Companies mentioned in this report are:

Standard and Poors RatingsXpress Credit Research provides in-depth coverage of international corporates, financial institutions, insurance companies, utilities, sovereigns and structured finance programs. RatingsXpress Credit Research lets users determine the credit rating of holdings and identify key factors underlying an issuer's creditworthiness, distinguishes the different risk exposures for new and existing deals, and provides an understanding of how their analysts interpret key regulatory, political and environmental events and their economic impact.

Research Type: Commentary
Criteria articles describe the thought process and methodology Standard & Poor's analysts use in determining ratings. These commentary pieces discuss both the quantitative (economic and financial) and qualitative (business analysis and caliber of management) aspects of the analysis, as well as legal issues.

Note: Product cover images may vary from those shown
2 of 2
Note: Product cover images may vary from those shown




Our Clients

  • Fluidigm Corporation
  • Apple, Inc.
  • CEVA Santé Animale
  • Abbott Laboratories Ltd.
  • Merck Group
  • Allergan Inc.
  • Pfizer Inc.